Description
The Integrated Hematologic Neoplasms Diagnostic Platform at ISABIAL is equipped with state‑of‑the‑art, cutting‑edge technology for the molecular diagnosis and research of neoplasms, including lymphomas, myelomas, and leukemias. The team is composed of highly recognized researchers with extensive expertise in key areas such as next‑generation flow cytometry, minimal residual disease, cell separation and sorting, cytogenetics through in situ hybridization, genome optical mapping, molecular biology, and high‑throughput sequencing (NGS).
In addition, this unit is equipped with the latest specialized technology, including 12‑channel cytometers, a 15‑channel sorter (CytoFLEX SRT), Illumina MiSeq and NextSeq 1000 sequencers, and the Bionano Saphyr system for genome optical mapping.
Thanks to the combination of cutting‑edge technology and a highly specialized approach, the unit provides accurate diagnoses and innovative solutions for the management of hematological neoplasms.
Services
- Consulting and methodological advisory services for the implementation of diagnostic platforms in the field of hemato‑oncology
- Interpretation of tests and results by a specialist physician in Advanced Hematologic Diagnostics and Molecular Biology
- Preparation of integrated cytometry/cytogenetics/molecular biology reports with a diagnostic conclusion consistent with the criteria, nomenclature and coding of the current WHO classification
- Flow cytometry techniques for the detection of relevant cell populations, diagnostic studies and monitoring of Minimal Residual Disease across different pathologies
- Techniques for the separation and isolation of cell populations through sorting with up to 15 parameters
- In situ hybridization (FISH) techniques in the field of hemato‑oncology
- Extraction of nucleic acids from cell suspensions and tissues, including DNA, RNA and cell‑free circulating plasma DNA
- Liquid biopsy of solid tumors, particularly those of hematologic origin
- Real‑time PCR for the detection and/or quantification of specific DNA fragments, as well as digital PCR
- Massive sequencing (NGS) techniques for the analysis of different hematologic neoplasms, enabling the detection of both germline and somatic mutations. Copy‑number variation analysis is also included
- Whole‑exome sequencing for rare diseases
- In the process of implementation, genomic optical mapping
Equipment
- DxH520 Automated Cell Counter, Beckman Coulter
- BX41 Fluorescence Microscope, Olympus
- Imager.Z2 Automated FISH Microscope, Zeiss
- FISH ThermoBrite Incubator
- 2 DxFLEX Cytometers, Beckman Coulter
- SORTER CYTOFLEX-SRT, BECKMAN COULTER
- EZ1 Advanced XL Extraction Robot, Qiagen
- EZ2 Extraction Robot, Qiagen
- QuantStudio 5 Real‑Time Thermocycler, Applied Biosystems
- Rotor‑Gene Q Real‑Time Thermocycler, Qiagen
- MiSeq Sequencer, Illumina
- NextSeq 1000/2000 Sequencer, Illumina
- PythoN Junior Tissue Dissociator, Singleron
- Saphyr System Genome Optical Mapping Platform, Bionano
- ROBOT PREPARADOR DE LIBRERIAS HAMILTON
- MD Stainer Automated FISH Robot, Vitro‑Máster Diagnóstica
- QIAcuity Digital PCR System
- Single‑Cell Analysis System, Singleron Biotechnologies
Teams
Fabián Tarín, Coordinator and Head of the Integrated Hematologic Neoplasms Diagnostic Unit, and Chief of the Hematology Department at Alicante General University Hospital Doctor Balmis.
Paula Piñero, Coordinator of the Integrated Hematologic Neoplasms Diagnostic Unit, PhD in Biology, Molecular Biologist, and holder of a Master’s Degree in Molecular Oncology.
Vanesa Díaz, Associate Physician in the Hematology Department at Alicante General University Hospital Doctor Balmis.
Elena Marín, Associate Physician in the Hematology Department at Alicante General University Hospital Doctor Balmis.
Marina González, Hematology Resident Physician at Alicante General University Hospital Doctor Balmis.
Rocío González, PhD in Biology, Molecular Biologist, and holder of a Master’s Degree in Neuroscience.
Pilar Ruiz, María Amparo Mollá, Laura Blázquez, and Lucía Ramón, Senior Laboratory Technicians.